BioVersys AG Company Description

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.

It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL).

The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections.

It has a research and license option agreement with Shionogi & Co., Ltd. to develop novel ansamycin leads from BV500 program into clinical candidates.

The company was founded in 2008 and is based in Basel, Switzerland.

BioVersys AG

Country	Switzerland
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	27
CEO	Marc Gitzinger

Contact Details

Address: Hochbergerstrasse 60c Basel, 4057 Switzerland
Phone	41 61 551 51 20
Website	bioversys.com

Stock Details

Ticker Symbol	BIOV
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	CHF
ISIN Number	CH0210362643
SIC Code	2834

Key Executives

Name	Position
Dr. Marc Gitzinger	Chief Executive Officer, Co-founder and Director
Hernan Santiago Levett CPA	Chief Financial Officer
Dr. Daniel Ritz	Chief Scientific Officer
Fiona Gao EMBA, L.L.M.	Head of Legal
Philipp Schmid	Head of Finance
Dr. Jonathan James Butcher	Head of Business Development and Alliance Management
Dr. Glenn E. Dale	Chief Development Officer
Dr. Jurgen Jager	Head of Chemistry, Manufacturing and Controls
Dr. Nawaz Khan	Head of Research
Dr. Alessia Michelotti	Head of Chemistry